This has contributed to the characterization of the mechanisms by which glucagon-like peptide-1 receptor agonists promote body mass reduction and has opened new windows of opportunity for the development of drugs to treat obesity. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.